Bullish Case: ALPHA3’s reported MRD advantage (58% versus 16%) and improving site execution could validate allogeneic CAR-T efficacy. If durability and CRS/ICANS remain acceptable, short covering and call-heavy positioning could extend the rebound from $1.16 a year ago. The thin positive tail in Helium’s return surface leaves room for a sharp rerating, particularly ahead of the anticipated mid-2027 readout.

Bearish Case: ALLO remains 91.4% below its five-year level, with financing and clinical-duration risk unresolved. Helium’s return surface is concentrated in modest losses with deep downside observations, while SPY volatility shows persistent lower-strike, longer-dated risk premia. Extremely wide ALLO option markets and high implied vol indicate fragile price discovery; weak durability, safety deterioration, or an offering could reverse the rebound quickly.

Potential Outcomes:

1. 35% $1.70–$2.50: mixed data, dilution concerns; base case.
2. 25% $2.50–$3.50: durable MRD and manageable toxicity.
3. 25% $1.20–$1.70: financing or weak efficacy.
4. 10% <$1.20: serious safety/futility.
5. 5% >$3.50: partnership.

Oracle: above $2.15 with falling downside IV is bullish; below $1.85 with rising put IV is bearish. Watch Sep 18, Nov 20, Feb 19 expiries and the mid-2027 readout.

August 25, 2026